Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence

Eyes Post-Xtandi Revenues

 
• By Ian Haydock and Lisa Takagi

Astellas set to acquire private US firm to add to its strategic capabilities in ophthalmology focus area, along with another revenue pillar as it prepares for Xtandi expiry. 

Astellas notes a high expectation for Iveric Bio's clinical candidate ACP
Astellas eyes high-need ophthalmology indication and another revenue pillar in Iveric deal • Source: Shutterstock

More from Business

More from Scrip